Financials Guangxi LiuYao Group Co., Ltd

Equities

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-13 EDT			5-day change	1st Jan Change
23.79 ^CNY	+1.88%		+3.12%	+25.74%

04-25	Guangxi LiuYao Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-22	Guangxi Liuyao Gets Shanghai Bourse's Nod to Issue Shares	MT

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	8,653	7,769	6,888	6,763	6,808	9,436	-	-
Enterprise Value (EV) ¹	8,990	7,906	6,888	6,763	6,808	9,436	9,436	9,436
P/E ratio	12.6 x	10.9 x	12.2 x	9.62 x	8.05 x	8.84 x	7.35 x	6.08 x
Yield	2.02%	2.79%	-	-	-	-	-	-
Capitalization / Revenue	0.58 x	0.5 x	0.4 x	0.35 x	0.33 x	0.41 x	0.37 x	0.33 x
EV / Revenue	0.58 x	0.5 x	0.4 x	0.35 x	0.33 x	0.41 x	0.37 x	0.33 x
EV / EBITDA	8.85 x	7.71 x	6.47 x	6.61 x	5.8 x	5.63 x	4.83 x	4.1 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	1.99 x	1.54 x	1.26 x	1.16 x	1.06 x	1.16 x	1.04 x	0.92 x
Nbr of stocks (in thousands)	360,103	360,691	361,740	362,228	359,813	396,620	-	-
Reference price ²	24.03	21.54	19.04	18.67	18.92	23.79	23.79	23.79
Announcement Date	4/22/20	2/24/21	3/30/22	2/27/23	3/20/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	14,857	15,670	17,135	19,053	20,812	23,158	25,737	28,512
EBITDA ¹	977.8	1,008	1,064	1,024	1,175	1,676	1,955	2,300
EBIT ¹	896.6	896.6	753.1	890.1	1,044	1,310	1,574	1,900
Operating Margin	6.03%	5.72%	4.4%	4.67%	5.01%	5.65%	6.12%	6.66%
Earnings before Tax (EBT) ¹	904.6	918.2	754.7	890.4	1,043	1,308	1,573	1,900
Net income ¹	685.4	715.8	563.8	701.5	849.6	1,021	1,228	1,484
Net margin	4.61%	4.57%	3.29%	3.68%	4.08%	4.41%	4.77%	5.21%
EPS ²	1.900	1.970	1.560	1.940	2.350	2.690	3.235	3.910
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	0.4857	0.6000	-	-	-	-	-	-
Announcement Date	4/22/20	2/24/21	3/30/22	2/27/23	3/20/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	337	137	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	0.3451 x	0.1361 x	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	16.9%	15.4%	10.7%	12.3%	13.5%	13.2%	14.1%	15%
ROA (Net income/ Total Assets)	6.31%	5.21%	-	-	-	-	-	-
Assets ¹	10,866	13,745	-	-	-	-	-	-
Book Value Per Share ²	12.10	14.00	15.10	16.10	17.80	20.40	22.90	25.90
Cash Flow per Share ²	1.140	1.830	0.9200	1.400	1.640	2.510	3.240	3.060
Capex ¹	231	250	264	183	173	193	214	235
Capex / Sales	1.55%	1.59%	1.54%	0.96%	0.83%	0.83%	0.83%	0.83%
Announcement Date	4/22/20	2/24/21	3/30/22	2/27/23	3/20/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.79 CNY

Average target price

31.29 CNY

Spread / Average Target

+31.53%

	1st Jan change	Capi.
GUANGXI LIUYAO GROUP CO., LTD	+25.74%	1.28B
MCKESSON CORPORATION	+19.14%	72.09B
CARDINAL HEALTH, INC.	-3.34%	23.88B
SINOPHARM GROUP CO. LTD.	+10.27%	8.89B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+12.67%	8.46B
HUADONG MEDICINE CO., LTD	-17.41%	8.29B
H. LUNDBECK A/S	+9.65%	4.9B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+21.40%	4.34B
EBOS GROUP LIMITED	-1.41%	3.98B
GALENICA AG	-1.99%	3.89B